(2E)-N-[(1R)-1-{1-cyclopentyl-4-oxo-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-6-yl}ethyl]-3-(3-hydroxyphenyl)prop-2-enamide

ID: ALA5277578

Chembl Id: CHEMBL5277578

Max Phase: Preclinical

Molecular Formula: C21H23N5O3

Molecular Weight: 393.45

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H](NC(=O)/C=C/c1cccc(O)c1)c1nc2c(cnn2C2CCCC2)c(=O)[nH]1

Standard InChI:  InChI=1S/C21H23N5O3/c1-13(23-18(28)10-9-14-5-4-8-16(27)11-14)19-24-20-17(21(29)25-19)12-22-26(20)15-6-2-3-7-15/h4-5,8-13,15,27H,2-3,6-7H2,1H3,(H,23,28)(H,24,25,29)/b10-9+/t13-/m1/s1

Standard InChI Key:  GCXNTFCQBBJOBA-WTNCMQEWSA-N

Alternative Forms

  1. Parent:

    ALA5277578

    ---

Associated Targets(Human)

PDE9A Tchem Phosphodiesterase 9A (1131 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 393.45Molecular Weight (Monoisotopic): 393.1801AlogP: 2.83#Rotatable Bonds: 5
Polar Surface Area: 112.90Molecular Species: NEUTRALHBA: 6HBD: 3
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 8.79CX Basic pKa: 0.16CX LogP: 2.16CX LogD: 2.15
Aromatic Rings: 3Heavy Atoms: 29QED Weighted: 0.58Np Likeness Score: -0.97

References

1. Nadur NF, de Azevedo LL, Caruso L, Graebin CS, Lacerda RB, Kümmerle AE..  (2021)  The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.,  212  [PMID:33412421] [10.1016/j.ejmech.2020.113123]

Source